Interaction between atazanavir and fosamprenavir in the treatment of HIV-infected patients.
Khanlou
Homayoun
H
Bhatti
Laveeza
L
Farthing
Charles
C
D019380:Anti-HIV Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D023241:Antiretroviral Therapy, Highly Active; D000069446:Atazanavir Sulfate; D002219:Carbamates; D004334:Drug Administration Schedule; D004347:Drug Interactions; D005663:Furans; D015658:HIV Infections / Q000188:drug therapy*; D006801:Humans; D009842:Oligopeptides / Q000008:administration & dosage / Q000627:therapeutic use*; D010755:Organophosphates / Q000008:administration & dosage / Q000627:therapeutic use*; D011725:Pyridines / Q000008:administration & dosage / Q000627:therapeutic use*; D013449:Sulfonamides / Q000008:administration & dosage / Q000627:therapeutic use*; D017211:Treatment Failure; D014766:Viremia / Q000517:prevention & control
D019380:Anti-HIV Agents; D002219:Carbamates; D005663:Furans; D009842:Oligopeptides; D010755:Organophosphates; D011725:Pyridines; D013449:Sulfonamides; D000069446:Atazanavir Sulfate; C095108:amprenavir; C426859:fosamprenavir